PCN12: CHANGES IN OUTPATIENT DRUG COSTS FOR CANCER PATIENTS, 1995 vs 1998  by Halbert, RJ et al.
354 Abstracts
PCN10
COMPARISON OF COSTS AND EFFECTS OF 
PROPHYLACTIC CLODRONATE FOR THE 
PREVENTION OF SKELETAL RELATED EVENTS 
IN PATIENTS WITH ADVANCED BREAST 
CANCER IN POLAND
Orlewska E
Unimed Research Centre for Pharmacoeconomics, Warsaw, 
Poland
OBJECTIVE: to estimate the costs and effects of clo-
dronate vs placebo in prevention of bone complications
in metastatic breast cancer in Poland. METHODS: The
model for the Polish health care context was developed,
based on the use of clinical data from literature and local
data on health care resource utilization and unit cost.
Only direct medical costs are analyzed. The perspective
of health-care payers and time horizon of 18 months
were taken. In the cost-effectiveness analysis the primary
clinical outcomes for measuring success in the analysis
were the avoided skeletal related events (SRE), which
were defined as pathological fractures, irradiation and
episodes of hypercalcaemia. The one-way sensitivity analysis
and threshold analysis were performed. RESULTS: The
costs of avoiding of SRE for clodronate vs placebo was
5292–5404 PLN. This value was lower then costs of
treatment of pathological fractures (7,000–40,000 PLN) and
higher than treatment of hypercalcaemia or irradiation
episode (2,200–2,600 PLN). The results were most sensi-
tive to the costs of treatment of pathologic fractures and
number of SRE avoided. CONCLUSION: Clodronate
therapy for advanced breast cancer offers substantial
benefit at a reasonable cost to the Polish health care sys-
tem, but in comparison to pamidronate is less cost-effective.
PCN11
PAYER COSTS OF PANCREATIC CANCER IN A 
NONELDERLY MEDICAID POPULATION
Malkin JD1, Pelletier EM1, Van Gool R2, Goss TF1
1Covance Health Economics and Outcomes Services Inc., 
Washington, DC, USA; 2Janssen Pharmaceutica Inc., Beerse, 
Belgium
OBJECTIVE: The purpose of this study was to estimate
the payer costs of pancreatic cancer for a nonelderly
Medicaid population and to provide a breakdown of
costs by type of care. METHODS: We performed a retro-
spective analysis of California Medicaid (Medi-Cal) data
linked by encrypted social security number to the Califor-
nia Department of Health Services Vital Statistics data-
base. We limited the sample to patients who were contin-
uously enrolled in Medi-Cal from six months prior to
their first pancreatic cancer diagnosis through death or
through December 31, 1998, whichever occurred first.
Patients must have had at least two diagnoses of pancre-
atic cancer or one diagnosis and a cause of death of pan-
creatic cancer. We excluded elderly patients (65 years)
because most of their medical bills are paid by Medicare
not Medicaid, which is a limitation in these data. We esti-
mated costs using the Kaplan-Meier Sample Average,
which results in consistent cost estimates if the censoring
mechanism is independent of survival and cost, a condi-
tion that is satisfied in the present analysis. All cost esti-
mates were expressed in 1999 U.S. dollars. RESULTS: Of
410 Medi-Cal patients meeting the study inclusion crite-
ria, the mean cost per patient for all services was $19,191.
The mean inpatient facility cost (including inpatient che-
motherapy) was $11,435 (59.6% of total costs) and the
mean cost of outpatient clinic visits was $2,416 (12.6%
of total costs). The mean cost of hospital outpatient visits
and hospice care was $828 (4.3% of total costs) and
$1,096 (5.7% of total costs), respectively. The mean cost
of outpatient chemotherapy agents was just $178 (0.9%
of total costs). Only 105 patients (25.6% of our sample)
received outpatient chemotherapy. CONCLUSION: This
analysis presents estimates of the payer cost of pancreatic
cancer among nonelderly Medi-Cal patients. Similar ex-
amination of costs among elderly patients is warranted.
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CHANGES IN OUTPATIENT DRUG COSTS FOR 
CANCER PATIENTS, 1995 vs 1998
Halbert RJ1,3, Zaher C3, Wade S3, Malin J2,5, Dubois RW3, 
Lawless G5
1Departments of Community Health Sciences, University of 
California, Los Angeles, CA, USA; 2Department of Medicine, 
University of California, Los Angeles, CA, USA; 3Protocare 
Sciences, Inc., Santa Monica, CA, USA; 4RAND Corporation, 
Santa Monica, CA, USA; 5Amgen, Inc., Thousand Oaks, CA, USA
OBJECTIVE: To quantify and characterize trends in out-
patient pharmaceutical expenditures in-patients diagnosed
with cancer. METHODS: Medical and pharmaceutical
costs (claims) from a large US managed care population
were utilized. Members with a confirmed diagnosis of
cancer were identified for the years 1995 and 1998.
Transaction costs were compiled for all outpatient drugs,
and compared between years. Drugs were grouped into
four categories: (1) chemotherapy; (2) chemotherapy ad-
juncts (i.e., drugs which enhanced or extended chemo-
therapy treatment); (3) supportive therapy (i.e., drugs to
treat complications or symptoms related to cancer); and
(4) drugs for routine patient conditions unrelated to can-
cer. RESULTS: There were $17.9 million in claims for
drugs in 1995, rising to $27.9 million in 1998, an in-
crease of over $10 million. Chemotherapy was the largest
driver of the cost increase, representing 52.4% of the to-
tal increase ($5.3 million). Routine patient drugs unre-
lated to their cancer therapy were the second most im-
portant cost driver, accounting for 31% of the increase
($3.1 m). Supportive therapies were third, and accounted
for 12% of the total increase ($1.2 m): among this group,
antidepressants showed the largest increase in cost, fol-
lowed by gastrointestinal agents and analgesics. Chemo-
therapy adjuncts as a class had the smallest impact on to-
tal cost increases—4.8% of the total increase, or $0.5
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million. Within the adjunct group, growth factors (at
4.2%) accounted for the largest proportion of the cost in-
crease, while antiemetics (the largest dollar amount) de-
creased between 1995 and 1998. CONCLUSION: Che-
motherapy accounted for the majority of the total increase
in pharmaceutical cost in-patients with cancer. Drugs
used in the treatment of routine conditions (i.e., not can-
cer-related) were the second largest cost drivers. Support-
ive therapy was the third largest cost driver. Of the groups
studied, chemotherapy adjuncts had the smallest impact
on total drug cost increases.
PCN13
MANAGEMENT OF LUNG CANCER IN FRANCE
Schmitt C1, Vergnenegre A2, Schuller-Lebeau MP3, Frappé M1, 
Bouin O3
1MDS Pharma Services, Sèvres, France; 2Centre Hospitalier 
Universitaire de Limoges, Limoges, France; 3Laboratoire 
Aventis, Paris, France
OBJECTIVE: To determine treatment patterns and cost
associated with the management of lung cancer in France
from the perspective of French hospitals by means of a
retrospective chart review. METHODS: Estimates were
based on a retrospective review of medical care consump-
tion in patients diagnosed with either small cell lung can-
cer (SCLC) or non small cell lung cancer (NSCLC) be-
tween 06/98 and 06/99 and followed until 09/99. Quotas
were defined by type and stage of lung cancer according
to available epidemiological data. Patients were identified
at a representative sample of 11 hospital centres in
France. Costs were estimated from date of diagnosis until
death or 16 months follow-up. Costs were adjusted for
censoring by means of a method described by Lin et al.
(Biometrics, 1997). RESULTS: 439 patient charts were
reviewed, including 92 SCLC and 357 NSCLC. Mean age
at diagnosis was 62, sex ratio was 82% male, 18% fe-
male. Survival at 12 months was 36% for SCLC and
ranged between 79% and 32% for NSCLC depending on
stage at diagnosis. All patients with limited-stage SCLC
received chemotherapy and 84% benefited from radio-
therapy. Of patients with disseminated SCLC, 91% re-
ceived chemotherapy and 49% palliative radiotherapy.
Patients with stage I–III NSCLC were treated with sur-
gery (43%), chemotherapy (71%) and/or radiotherapy
(73%). Stage IV NSCLC patients had surgery (15%) and/
or chemotherapy (91%) and/or radiotherapy (65%). Pre-
liminary analyses indicate that the management of ad-
verse events accounted for more than 25% of the total
cost. CONCLUSION: Considering the high cost manage-
ment of adverse events and radiotherapy, new chemo-
therapy treatments increasing overall survival with ac-
ceptable toxicity profile and decreasing radiotherapy acts,
would have a significant economic value. Updated results
will be presented.
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THE USE OF TRANSDERMAL FENTANYL (FEN) 
VERSUS MORPHINE (MOR) IN CANCER PAIN 
PATIENTS IN ISRAEL
Nuyts GD1, Fridman N2, De Cooman F3
1Health Economics, Janssen Pharmaceutica, Beerse, Belgium; 
2Maccabi, Tel-Aviv, Israel; 3SPS, Mechelen, Belgium
OBJECTIVES: To study the cost of cancer pain manage-
ment in the Maccabi database. This database delivers in-
formation on diagnosis, treatment and costs. Costs were
compared for patients that were on MOR and switched
to FEN and costs were assessed relative to total treatment
cost. METHODS: A selection was made of all cancer pa-
tients (N  1082) treated with strong opioids during
1997–1998. Fifty-two percent were women and average
age 62 years. Fifteen percent of the patients had skin can-
cer and 10% was reported with lung cancer. Patients
were divided in four different groups based upon the se-
quence of strong opioid use: FF is the group that was on
FEN, MF was the group that started on MOR but
switched to FEN, FM vice versa and MM were on MOR
throughout. RESULTS: In the MF group significantly
fewer infections and abdominal pain were reported by
patients after switching to FEN. Also a reduction in
drugs used was observed after switching to FEN: laxa-
tives, H2-blockers, anti-emetics, anti-diarrhea, antibiot-
ics, NSAIDs and other pain treatments. The total mean
daily drug acquisition cost was 162 New Israelian Shekel
(NIS) for the MOR period and 115 NIS while on FEN, a
reduction resulting from reduced need for concomittant
medication. The cost for pain management accounted for
3.1% (MM) to 6.7% (MF) of the total expenses, indicat-
ing the relatively low impact the choice of pain strategy
has on total cost. CONCLUSION: This database analysis
indicates that FEN treatment generates fewer costs com-
pared to MOR treatment in patients switching from
MOR to FEN. Without an adequate control group it is
difficult to determine whether this reflects resource utili-
zation related to the selected pain treatment or changed
medical practice in the course of cancer treatment. Over-
all the cost of pain management is low relative to the to-
tal cost for these patients.
PCN15
A METHODOLOGY FOR IMPLEMENTING 
QUALITY-ADJUSTED DISEASE FREE SURVIVAL 
(QADFS) WITH MULTIDIMENSIONAL QUALITY 
OF LIFE (QoL) INSTRUMENTS IN
CANCER TRIALS
Singh A, Padley RJ, Ashraf T
Abbott Laboratories, Abbott Park IL, USA
QoL is an important factor in the evaluation of new can-
cer therapies. Conventional analyses of responses in ther-
apeutic trials fail to account for treatment effects on pa-
tient’s perception of their health status and their general
well being. OBJECTIVE: To develop a methodology for
